Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 bosutinib study in children with chronic myeloid leukemia resistant or intolerant to prior tyrosine kinase inhibitor therapy
MOH_2017-07-20_000654Phase 2Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bosutinib in chronic myelogenous leukemia (CML) (3 arms), sponsored by Erasmus MC. Primary endpoints: Safe and recommended bosutinib dose and Anti-leukemia activity. Planned start May 2017; status: not yet recruiting.
02
Drugs
bosutinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on MOH_2017-07-20_000654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-07-20_000654.